Evidence mapPaperPMID 38690938Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2024

Hyperglycemia impairs EAAT2 glutamate transporter trafficking and glutamate clearance in islets of Langerhans: implications for type 2 diabetes pathogenesis and treatment.

Alessandra Galli, Stefania Moretti, Nevia Dule, Eliana Sara Di Cairano, Michela Castagna, Paola Marciani, Cristina Battaglia, Federico Bertuzzi, Paolo Fiorina, Ida Pastore and 4 more

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Alessandra GalliLaboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
Stefania MorettiLaboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
Nevia DuleLaboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
Eliana Sara Di CairanoLaboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
Michela CastagnaLaboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
Paola MarcianiLaboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
Cristina BattagliaDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy.ORCID 0000-0003-3025-9657
Federico BertuzziDiabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy.
Paolo FiorinaDepartment of Biomedical and Clinical Sciences "L. Sacco,"Università degli Studi di Milano, Milan, Italy.
Ida PastoreEndocrinology Unit, ASST Fatebenefratelli-Sacco, Milan, Italy.
Stefano La RosaUnit of Pathology, Department of Oncology, ASST Sette Laghi, Varese, Italy.
Alberto DavalliDiabetes and Endocrinology Unit, Department of Internal Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Franco FolliDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.ORCID 0000-0001-9824-5222
Carla PeregoLaboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.ORCID 0000-0003-3027-1779
University of Milan · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITBoston Children's Hospital · USUniversity of Insubria · ITVita-Salute San Raffaele University · IT

Funding

Relmada Therapeutics
6 · The paper itself

Abstract

Pancreatic endocrine cells employ a sophisticated system of paracrine and autocrine signals to synchronize their activities, including glutamate, which controls hormone release and β-cell viability by acting on glutamate receptors expressed by endocrine cells. We here investigate whether alteration of the excitatory amino acid transporter 2 (EAAT2), the major glutamate clearance system in the islet, may occur in type 2 diabetes mellitus and contribute to β-cell dysfunction. Increased EAAT2 intracellular localization was evident in islets of Langerhans from T2DM subjects as compared with healthy control subjects, despite similar expression levels. Chronic treatment of islets from healthy donors with high-glucose concentrations led to the transporter internalization in vesicular compartments and reduced [H

Indexed as

Diabetes Mellitus, Type 2Excitatory Amino Acid Transporter 2Glutamic AcidHyperglycemiaIslets of LangerhansAdultAgedAnimalsFemaleHumansInsulin-Secreting CellsMaleMiddle AgedPhosphatidylinositol 3-KinasesProtein TransportProto-Oncogene Proteins c-aktExcitatory Amino Acid Transporter 2Glutamic AcidPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSLC1A2 protein, humanEAAT2/GLT1glutamateislets of LangerhansPI3Ktype 2 diabetes mellitus

Identifiers

PMID38690938
PMCPMC11390119
OpenAlexW4396552350

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.